Aileron Therapeutics to Present at Upcoming Investor Conferences
04 janv. 2022 08h45 HE
|
Aileron Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
20 déc. 2021 10h56 HE
|
Aileron Therapeutics, Inc.
BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a...
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
12 nov. 2021 07h50 HE
|
Aileron Therapeutics, Inc.
Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned...
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
07 oct. 2021 09h22 HE
|
Aileron Therapeutics, Inc.
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924’s...
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
30 sept. 2021 16h30 HE
|
Aileron Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
10 sept. 2021 08h30 HE
|
Aileron Therapeutics, Inc.
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic...
Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
27 août 2021 07h45 HE
|
Aileron Therapeutics, Inc.
Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal...
Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
11 août 2021 16h20 HE
|
Aileron Therapeutics, Inc.
Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end...